35 KB73 KB32 KB192920262001Meden-Vrtovec, HelenaPožlep, Barbaraštevilka:10letnik:70str. 525-529ISSN:1318-0347COBISSID:14051289URN:URN:NBN:SI:doc-A4VG4FNMenSlovensko zdravniško društvoZdravniški vestnikFertilizacija in vitroFertilization in vitroGenital diseases, femaleGenitalne bolezni ženskeginekologijaGonadotropini hipofizniIndukcija ovulacijeInfertility, femaleJajčnik, novotvorbejajčnikiMenotropinsneplodnostNeplodnost ženskaOvarian neoplasmsOvulation inductionrak (medicina)UltrasonographyOvulation induction agents and ovarian cancer| Induktorji ovulacije in rak jajčnika|Background. Ovarian cancer is the most frequent cause of death among gynecologic malignancies. Epidemiological data show that environmental, hormonal and genetic factors are etiologically significant. Beside the alreadyknown risk factors, ovulation induction agents have been reported as risk factors in literature since 1986. Over the last two decades, ovulation induction agents have been widely used in various assisted reproduction techniques (ART). This study focused on the question whether in patients receiving ovulation induction agents the risk for developing gpathologic processes on the ovaries was higher than in those not receiving them, and whether they were related to the dose and type of ovulation induction agent. Methods. In a prospective study 380 subjects were enrolled. The study group consisted of 280 women who had undergone an ARTprocedure three or more times. The control group consisted of 220 infertile women, never included in an ART procedure. All the enrolled subjects underwent the same examinations: a detailed gynecological history was taken, pelvic examination and vaginal ultrasound were performed, and a blood sample for tumour marker CA 125 determination was taken. Statistical analysis was done using Chi-square test, t test and logistic regression. Results. Ultrasound examination revealed pathology on the genital tract in 136 women in the study group and in 60 womenin the control group. Differences in the incidence of ovarian, tubal and uterine pathology were not statistically significant. The analysis of the medical records showed that the incidence of ovarian pathology was significantly higher in the study than in the control group (p < 0.05). We found no corredation between the incidence of ovarian pathology and type or dose of ovulation induction agent Increased CA 125 levels were found in 12 women. In none of the women neither malignant nor borderline malignant diseasewas found. (Abstract truncated at 2000 characters)Izhodišča. Rak jajčnika je najpogostejši vzrok smrti med ginekološkimi malignimi obolenji. Epidemiološki podatki kažejo, da so etiološko pomembni dejavniki okolja, hormonski in genetski dejavniki. Ob že znanih dejavnikih se od leta 1986 v literaturi omenjajo tudi induktorji ovulacije (10), ki se zadnji dve desetletji veliko uporabljajo v postopkih oploditve z biomedicinskopomočjo (OBMP). Temelj naše raziskave je bilo vprašanje, ali je pri bolnicah; ki so dobivale IO, tveganje za nastanek patoloških procesov na jajčnikih večje kot pri bolnicah, ki IO niso dobivale, ter ali so ti odvisni od odmerka ali vrste IO. Metode. V prospektivno študijo smo vključili 380 preiskovank. Študijsko skupino je sestavljalo 260 preiskovank, ki so bile v postopke OBMP vk jučene tri- in večkrat. Kontrolno skupino je sestavljalo 120 neplodnih preiskovank, ki v te postopke še niso bile vključene. Pri vseh preiskovankah smo opravili usmerjeno ginekološko anamnezo, ginekološki pregled, vaginalni ultrazvočni pregled ter odvzeli kri za tumorski marker CA 125. Statistično analizo rezultatov smo naredili s Studentovim t-testom, X2 testom ter logistično regresijo. (Izvleček skrajšan na 2000 znakov)TEXTznanstveno časopisjejournalsSlovenian National E-content AggregatorNational and University Library of SloveniaSlovensko zdravniško društvo